Astec Lifesciences Ltd
Astec Lifesciences Ltd (ASTEC) last reported results for the quarter ended Jun 2026, with sales of ₹84 crore and net profit of ₹-19 crore. The stock last traded at ₹694, a market capitalisation of ₹1,547 crore. Over the past 52 weeks the stock has ranged between ₹512 and ₹942. Figures are as of 6 Oct 2026 and are not real time.
Astec Lifesciences Ltd share price and key metrics
- Current price
- ₹694
- Market cap
- ₹1,547 cr
- Book value
- ₹175
- ROE
- -25.2%
- ROCE
- -5.44%
- Dividend yield
- 0.00%
- 52w high / low
- 942/512
Metrics as of 6 Oct 2026. Not real time.
Track Astec Lifesciences Ltd
Cruxal reads every Astec Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Astec Lifesciences Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- -4%
- 3 Years
- -11%
- TTM
- 9%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 50%
- 10 Years
- 4%
- 5 Years
- -11%
- 3 Years
- -19%
- 1 Year
- -11%
- 10 Years
- 2%
- 5 Years
- -8%
- 3 Years
- -26%
- Last Year
- -25%
Astec Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹84 cr, down 7.7% from ₹91 cr a year earlier. Net profit was ₹-19 cr, up 42.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 |
| Expenses | 118 | 100 | 114 | 102 | 80 | 121 | 149 | 84 |
| Operating profit | -20 | -6 | 6 | -11 | -7 | 4 | 9 | -1 |
| OPM % | -20% | -6% | 4.6% | -12% | -9% | 3.2% | 6% | -0.8% |
| Other income | 2 | 2 | 1 | 1 | 1 | -1 | 3 | 1 |
| Interest | 9 | 10 | 10 | 11 | 8 | 7 | 8 | 8 |
| Depreciation | 11 | 11 | 12 | 11 | 10 | 11 | 12 | 11 |
| Profit before tax | -39 | -25 | -16 | -33 | -24 | -16 | -8 | -19 |
| Tax % | 0% | 61% | 3% | 0% | 0% | 0% | -2% | -0% |
| Net profit | -39 | -40 | -16 | -33 | -24 | -16 | -8 | -19 |
| EPS (₹) | -17.21 | -18.03 | -7.18 | -14.75 | -10.96 | -7.05 | -3.48 | -8.40 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Astec Lifesciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 | 441 |
| Operating profit | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -4 | 6 |
| OPM % | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1.3% | -17% | -1.0% | 1.3% |
| Net profit | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -81 | -67 |
| EPS (₹) | 8.57 | 15.65 | 16.03 | 21.21 | 29.04 | 40.12 | 11.41 | -20.95 | -60.16 | -36.32 | -29.89 |
TTM is the trailing twelve months to the most recent quarter.
Astec Lifesciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
| Reserves | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 | 368 |
| Borrowings | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | 449 |
| Other liabilities | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | 102 |
| Total liabilities | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
| Fixed assets | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 459 |
| CWIP | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | 463 |
| Total assets | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
As reported by the company. Total assets equal total liabilities by construction.
Astec Lifesciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 | -8 | -81 |
| Cash from investing | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 | -15 | -4 |
| Cash from financing | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | 24 | 94 |
| Net cash flow | 1 | -3 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 9 |
| Free cash flow | -1 | 15 | -37 | 123 | -111 | -80 | -42 | -125 | -24 | -86 |
| CFO / operating profit | 41% | 116% | 41% | 219% | 13% | 34% | 104% | -211% | 20% | 1,796% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Astec Lifesciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% | -5% |
| Debtor days | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 | 202 |
| Inventory days | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 | 169 |
| Days payable | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 | 107 |
| Cash conversion cycle | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 | 263 |
| Working capital days | 1 | -8 | -2 | 8 | 4 | 12 | -17 | -1 | -26 | -56 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Astec Lifesciences Ltd shareholding pattern
Promoters held 71.97% at Jun 2026, up from 70.87% at Jun 2025. FIIs 0.01% and DIIs 3.33%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.74% | 66.74% | 70.87% | 70.87% | 72.42% | 71.97% | 71.97% | 71.97% |
| FIIs | 0.53% | 1.20% | 0.25% | 0.02% | 0.00% | 0.04% | 0.03% | 0.01% |
| DIIs | 4.50% | 5.40% | 4.34% | 4.26% | 4.01% | 3.17% | 3.33% | 3.33% |
| Public | 28.20% | 26.64% | 24.53% | 24.84% | 23.57% | 24.82% | 24.67% | 24.69% |
| No. of shareholders | 19,727 | 19,057 | 18,689 | 18,549 | 18,276 | 22,293 | 21,041 | 19,889 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Astec Lifesciences Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find enclosed, certificate for the Quarter ended September 30, 2026.
Read the full analysis - Company Responds to Volume Movement Letter; No Financial Impact IndicatedCompany Updatelow impact
Cruxal's analysis: Astec Lifesciences Ltd issued a response to a volume movement letter on 2026-10-01. The…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed, intimation of closure of trading window.
Read the full analysis - Astec Lifesciences Ltd submits response to BSE query dated 18.09.2026Company Updatelow impact
Cruxal's analysis: Astec Lifesciences has filed a formal response to a query raised by the BSE on September…
Read the full analysis - Astec Lifesciences responds to BSE clarification request regarding recent stock price movementCompany Updatelow impact
Cruxal's analysis: Astec Lifesciences submitted a formal response to the BSE regarding an email dated…
Read the full analysis - Astec Lifesciences Ltd responds to BSE query regarding recent stock volume movementCompany Updatelow impact
Cruxal's analysis: Astec Lifesciences Ltd has submitted a formal response to the BSE regarding the recent…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.